Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 1, 2018
Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion, reported net income of $73 million and reported diluted earnings per share ("EPS") of $0.52 compared to a...
-
Feb 27, 2018Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018
Select Preliminary Unaudited Calendar Year 2017 Results Delivered strong calendar year 2017 GAAP ("reported") and adjusted net sales at the high end of previous guidance range and operating cash...
-
Feb 20, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of...
-
Feb 20, 2018
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ronald L. Winowiecki has been appointed Chief Financial Officer....
-
Feb 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on March 20, 2018 to shareholders of record on March 2,...
-
Feb 8, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018. The Company will also host a...
-
Jan 30, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Soolantra® (ivermectin) cream, 1%....
-
Jan 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate...
-
Jan 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol vaginal...
-
Jan 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene...
-
Jan 8, 2018- Uwe Röhrhoff, former Chief Executive Officer at Gerresheimer AG, appointed President, CEO and board member effective January 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of Uwe Röhrhoff as Chief Executive Officer,...
-
Jan 3, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac ophthalmic...
-
Jan 2, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference at 12:00 PM EST...
-
Nov 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Mycolog® II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1...
-
Nov 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Exalgo® 32mg extended release tablets (hydromorphone HCl) C-II. Exalgo® 32mg extended release...
-
Nov 21, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK...
-
Nov 10, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday,...
-
Nov 9, 2017
Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion, reported net income of $45 million and reported diluted earnings per share ("EPS") of $0.31 compared to a loss per share...
-
Nov 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19, 2017 to shareholders of record on...
-
Nov 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...
-
Oct 26, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2017 financial results on Thursday, November 9, 2017. The Company will also host a conference call...
-
Oct 26, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) brought by...
-
Oct 24, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...
-
Sep 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR...
-
Sep 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Sep 18, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and...
-
Aug 30, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference at 4:10 PM EDT on...
-
Aug 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR...
-
Aug 16, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Aug 10, 2017
Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net...
-
Aug 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on September 12, 2017 to shareholders of record on...
-
Aug 4, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso® (brimonidine) topical gel...
-
Jul 31, 2017
Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine...
-
Jul 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2017 financial results on Thursday, August 10, 2017. The Company will conduct a conference call at...
-
Jul 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray...
-
Jul 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart,...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%)...
-
Jun 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitartrate and homatropine methylbromide oral...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash...
-
Jun 14, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the "Early Tender Deadline") for...
-
Jun 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the forthcoming retirement of Chief Executive Officer John T....
-
Jun 2, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017....
-
May 31, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary ("Perrigo Finance"), have...
-
May 30, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer,...
-
May 30, 2017
Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and...